950649-21-5

Usage

Uses

Used in Pharmaceutical Synthesis:
2-(PIPERIDIN-4-YLOXY)PYRAZINE DIHYDROCHLORIDE is used as a key intermediate in the synthesis of pharmaceuticals, specifically for the production of 5-HT4 receptor agonists and antagonists. These compounds are integral in the development of medications targeting a variety of conditions.
Used in Neurodegenerative Disease Treatment:
In the field of neurology, 2-(PIPERIDIN-4-YLOXY)PYRAZINE DIHYDROCHLORIDE is used as a potential therapeutic agent for the treatment of neurodegenerative diseases. Its role in this application is based on its ability to interact with specific receptors that may help in managing the symptoms and progression of such diseases.
Used in Anti-Inflammatory Applications:
2-(PIPERIDIN-4-YLOXY)PYRAZINE DIHYDROCHLORIDE is used as an anti-inflammatory agent, leveraging its potential to modulate the immune response and reduce inflammation, which is a common factor in many diseases and conditions.
Used in Gastrointestinal Disorder Treatment:
In gastroenterology, 2-(PIPERIDIN-4-YLOXY)PYRAZINE DIHYDROCHLORIDE is used as a potential treatment for gastrointestinal disorders. Its application in this field is due to its capacity to influence the receptors involved in the regulation of gastrointestinal motility and function.
Used in Psychiatric Condition Management:
2-(PIPERIDIN-4-YLOXY)PYRAZINE DIHYDROCHLORIDE is used in the development of treatments for psychiatric conditions, where it may contribute to the modulation of neurotransmitter activity, potentially offering relief from symptoms associated with these disorders.

Upstream product

• 442199-08-8 tert-butyl 4-(pyrazin-2-yloxy)piperidine-1-carboxylate 

Relevant academic research and scientific papers

Discovery and SAR Evolution of Pyrazole Azabicyclo[3.2.1]octane Sulfonamides as a Novel Class of Non-CovalentN-Acylethanolamine-Hydrolyzing Acid Amidase (NAAA) Inhibitors for Oral Administration

Inhibition of intracellularN-acylethanolamine-hydrolyzing acid amidase (NAAA) activity is a promising approach to manage the inflammatory response under disabling conditions. In fact, NAAA inhibition preserves endogenous palmitoylethanolamide (PEA) from degradation, thus increasing and prolonging its anti-inflammatory and analgesic efficacy at the inflamed site. In the present work, we report the identification of a potent, systemically available, novel class of NAAA inhibitors, featuring a pyrazole azabicyclo[3.2.1]octane structural core. After an initial screening campaign, a careful structure-activity relationship study led to the discovery ofendo-ethoxymethyl-pyrazinyloxy-8-azabicyclo[3.2.1]octane-pyrazole sulfonamide50(ARN19689), which was found to inhibit human NAAA in the low nanomolar range (IC50= 0.042 μM) with a non-covalent mechanism of action. In light of its favorable biochemical, in vitro and in vivo drug-like profile, sulfonamide50could be regarded as a promising pharmacological tool to be further investigated in the field of inflammatory conditions.

HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE

The present invention provides a novel hydroxyquinoxaline carboxamide derivative that is useful for preventing and/or treating blood coagulation disorders. A compound represented by formula (i), or a pharmacologically acceptable salt thereof: wherein, each of R1 and R2 independently represents a group such as a hydrogen atom or a halogen atom; R3 represents a group such as a hydrogen atom; each of R4 and R5 independently represents a group such as a hydrogen atom, a halogen atom or a C1-4 alkyl group; each of R6 and R7 independently represents a hydrogen atom or a C1-4 alkyl group; X represents a group such as a C3-10 cycloalkyl group, C6-10 aryl group or a 5- to 10-membered heterocyclic group, which may be substituted with substituent(s) selected from substituent group α; Y represents a group such as -CO-, -O- or -NRa-, and Ra represents a group such as a hydrogen atom or a C1-4 alkyl group.